Show us the money: US payers demand value
This article was originally published in Scrip
Executive Summary
It's not enough to show that a new drug works in order to secure reimbursement by US health care payers; increasingly biotechnology and pharmaceutical companies must demonstrate that their products also cut costs related to the disease they are meant to treat.